Recurrent Neuroblastoma Completed Phase 1 Trials for Ipilimumab (DB06186)

Also known as: Neuroblastoma Recurrent

IndicationStatusPhase
DBCOND0028756 (Recurrent Neuroblastoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00060372Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerTreatment